A Study of Sotorasib in People With Non-Small Cell Lung Cancer
ConditionNon Small Lung Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received treatment for their cancer since it became advanced. (Participants have not received a "first-line therapy" since their cancer became advanced.)
Eligibility criteria
Qualifiers
Written informed consent
Biopsy-proven metastatic or recurrent non-small cell lung cancer
KRAS G12C mutation on prior tumor biopsy or cell-free DNA (cfDNA) testing
No prior therapy in the advanced setting
Disqualifiers
Symptomatic brain metastases
Any radiotherapy within 1 week of starting treatment on protocol
Any major surgery within 1 week of starting treatment on protocol
Exposure to prior adjuvant or consolidation anti-PD-1 or PD-(L)1 therapy for stage I-III disease within 12 weeks of start of initiation of sotorasib
Trial design
Treatments tested in this trial
- Sotorasib
Treatment groups
39 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov